December 4, 2012
Questcor Pharmaceuticals (Nasdaq: QCOR ) has decided to pay $0.20 per share to shareholders on Dec. 21 rather than its regularly scheduled Q1 payout, to get ahead of the fiscal cliff. One of the possibilities included in the fiscal cliff negotiations could raise dividend tax rates from their current 15% up to income tax rate percentages, so many companies are either giving special dividends or moving their regular dividends up into the next few weeks. Some have speculated that a number of these companies do this for not entirely generous reasons, in the cases of companies with a large percentage of internal ownership, but Questcor doesn't fall into that category, with insiders owning only 0.5% of its shares.
See more in the following video.
Questcor is one of the most debated names in all of biotech. Its premium priced drug, Acthar, is growing at a torrid pace -- and minting money in the process. However, recent events have created significant doubts about Questcor's future. Will insurance companies continue to cover the drug? Will a government investigation lead to huge fines? We highlight these high-profile issues inside our brand-new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.